Pioneering the Next Generation of
CAR-T Cell Therapies

Gracell is developing cell and gene therapies that
deliver fast, deep and durable responses for cancer patients

Our Mission

We are a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical needs in the treatment of cancer. We aim to disrupt conventional approaches to CAR-T cell therapies with our proprietary technology platforms—FasTCAR and TruUCAR.

FasTCART^™

Our autologous platform producing CAR-T cell therapies that utilize next-day manufacturing to deliver younger, less exhausted T cells with enhanced activities

TruUCART^™

Our allogeneic platform generating CAR-T cell therapies that are readily available off-the-shelf at lower cost for a broad patient base

Pipeline^™

We are developing a rich clinical-stage pipeline to unlock the long-held promise of CAR-T cell therapies

Latest News

Jun 2 2021

Gracell Biotechnologies Reschedules Clinical Update Conference Call and Webcast to June 14, 2021

May 26 2021

Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Dual-Targeting CAR-T with Overnight Manufacturing - a Novel Approach for Treatment of Multiple Myeloma

May 25 2021

Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in June

Pioneering the Next Generation of CAR-T Cell Therapies

Our Mission

FasTCART™

TruUCART™

Pipeline™

Latest News

Pioneering the Next Generation of
CAR-T Cell Therapies

FasTCART^™

TruUCART^™

Pipeline^™